Dechra Pharmaceuticals Plc Stock Cash Flow From Operations
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
Dechra Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Dechra Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dechra Pink Sheet. The fundamental analysis module provides a way to measure Dechra Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dechra Pharmaceuticals pink sheet.
Dechra |
Dechra Pharmaceuticals PLC Company Cash Flow From Operations Analysis
Dechra Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Dechra Pharmaceuticals Cash Flow From Operations | 122.9 M |
Most of Dechra Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dechra Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Dechra Pharmaceuticals PLC has 122.9 M in Cash Flow From Operations. This is 76.69% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The cash flow from operations for all United States stocks is 87.35% higher than that of the company.
Dechra Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dechra Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Dechra Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dechra Pharmaceuticals by comparing valuation metrics of similar companies.Dechra Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Dechra Fundamentals
| Return On Equity | 0.0896 | |||
| Return On Asset | 0.0478 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 4.04 B | |||
| Shares Outstanding | 56.92 M | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Book | 4.99 X | |||
| Price To Sales | 5.65 X | |||
| Revenue | 681.8 M | |||
| Gross Profit | 384.8 M | |||
| EBITDA | 178.9 M | |||
| Net Income | 58.2 M | |||
| Cash And Equivalents | 123.7 M | |||
| Cash Per Share | 2.29 X | |||
| Total Debt | 313.7 M | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 12.30 X | |||
| Cash Flow From Operations | 122.9 M | |||
| Earnings Per Share | 1.29 X | |||
| Number Of Employees | 2 K | |||
| Beta | 0.68 | |||
| Market Capitalization | 4.3 B | |||
| Total Asset | 1.29 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 1.29 B | |||
| Last Dividend Paid | 0.45 |
About Dechra Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dechra Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dechra Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dechra Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |